Department of Chemistry, Centre of Advanced Study, Banaras Hindu University, Varanasi 221005, India.
Eur J Med Chem. 2011 Oct;46(10):4769-807. doi: 10.1016/j.ejmech.2011.07.057. Epub 2011 Aug 16.
The therapeutic areas of infectious diseases and oncology have benefited from abundant scaffold diversity in natural products, able to interact with many specific targets within the cell and indeed for many years have been source or inspiration for the majority of FDA approved drugs. The present review describes natural products (NPs), semi-synthetic NPs and NP-derived compounds that have undergone clinical evaluation or registration from 2005 to 2010 by disease area i.e. infectious (bacterial, fungal, parasitic and viral), immunological, cardiovascular, neurological, inflammatory and related diseases and oncology.
传染病和肿瘤治疗领域得益于天然产物中丰富的骨架多样性，这些天然产物能够与细胞内的许多特定靶点相互作用，多年来一直是大多数获得 FDA 批准的药物的来源或灵感。本综述描述了 2005 年至 2010 年期间按疾病领域（即传染病（细菌、真菌、寄生虫和病毒）、免疫、心血管、神经、炎症和相关疾病以及肿瘤学）进行临床评估或注册的天然产物（NPs）、半合成 NPs 和 NP 衍生化合物。
